falsefalse

Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting - Episode 4

General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting
    EP. 2: Selecting Optimal 3L Colorectal Cancer Treatment
    EP. 3: Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment
    Now Viewing
    EP. 4: General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab
    EP. 5: Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC
    EP. 6: Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer
    EP. 7: Treatment Considerations With Regorafenib in Colorectal Cancer
    EP. 8: Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma
    EP. 9: FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
    EP. 10: Monitoring and AE Management Strategies with Fruquintinib in CRC
    EP. 11: Toxicity Considerations and Treatment Decisions in CRC
    EP. 12: Multidisciplinary Care for Patients with CRC
    EP. 13: Unmet Needs and Future Perspectives in Colorectal Cancer

    Related Content:

    InsightsVideo SeriesClinical
    Sequencing the Available T Cell– Engaging Therapies, and the Role of Bridging/Holding Therapy in RRMM
    Exploring the Treatment Options for RRMM
    Navigating Early-Line Treatment Options for HER2+ Metastatic Breast Cancer
    x